Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus ; volume:4 ; number:1 ; day:16 ; month:2 ; year:2024 ; pages:1-9 ; date:12.2024
Communications medicine ; 4, Heft 1 (16.2.2024), 1-9, 12.2024
- Urheber
-
Chiuppesi, Flavia
Zaia, John A.
Gutierrez-Franco, Miguel-Angel
Ortega-Francisco, Sandra
Ly, Minh
Kha, Mindy
Kim, Taehyun
Dempsey, Shannon
Kar, Swagata
Grifoni, Alba
Sette, Alessandro
Wussow, Felix
Diamond, Don J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s43856-024-00443-9
- URN
-
urn:nbn:de:101:1-2404230807398.594903891797
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chiuppesi, Flavia
- Zaia, John A.
- Gutierrez-Franco, Miguel-Angel
- Ortega-Francisco, Sandra
- Ly, Minh
- Kha, Mindy
- Kim, Taehyun
- Dempsey, Shannon
- Kar, Swagata
- Grifoni, Alba
- Sette, Alessandro
- Wussow, Felix
- Diamond, Don J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Recombinant modified Vaccinia Virus Ankara (MVA) vaccines efficiently protect cockatiels against parrot bornavirus infection and proventricular dilatation disease
Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice
Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
Correction: Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
Modelling the neuropathological consequences of HIV vaccines that confer partial protection
Repair of the Vaccinia virus genes B2R and B3R inhibits interferon production uponmodified Vaccinia virus Ankara infection
Functional characterization of modified vaccinia virus Ankara-encoded anti-apoptotic proteins
Presentation of recombinant proteins in modified vaccinia virus Ankara extracellular enveloped virions
Presentation of recombinant proteins in modified vaccinia virus Ankara extracellular enveloped virions
Recombinant modified Vaccinia Virus Ankara (MVA) vaccines efficiently protect cockatiels against parrot bornavirus infection and proventricular dilatation disease
Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice
Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
Correction: Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
Modelling the neuropathological consequences of HIV vaccines that confer partial protection
Repair of the Vaccinia virus genes B2R and B3R inhibits interferon production uponmodified Vaccinia virus Ankara infection
Functional characterization of modified vaccinia virus Ankara-encoded anti-apoptotic proteins
Presentation of recombinant proteins in modified vaccinia virus Ankara extracellular enveloped virions
Presentation of recombinant proteins in modified vaccinia virus Ankara extracellular enveloped virions
Recombinant modified Vaccinia Virus Ankara (MVA) vaccines efficiently protect cockatiels against parrot bornavirus infection and proventricular dilatation disease
Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice
Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
Correction: Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
Modelling the neuropathological consequences of HIV vaccines that confer partial protection
Repair of the Vaccinia virus genes B2R and B3R inhibits interferon production uponmodified Vaccinia virus Ankara infection
Functional characterization of modified vaccinia virus Ankara-encoded anti-apoptotic proteins
Presentation of recombinant proteins in modified vaccinia virus Ankara extracellular enveloped virions